`ECEIVED
`
`IN THE UNITED ST A TES DISTRICT COURT
`FOR THE DISTRICT OF NEW JERSEY
`
`I
`I
`' i
`
`FEB 2 3 2017
`
`. M
`AT 8:30
`WILLIAM T. WALSH .~
`CLERK
`
`I
`
`HORIZON PHARMA, INC., and POZEN,
`INC.,
`
`Civil Action No. 3: 15-cv-03. 27-MLC-DEA
`
`Plaintiffs,
`
`v.
`
`MYLAN PHARMACEUTICALS INC.,
`MYLAN LABORATORIES LIMITED, and
`MYLAN INC ..
`
`Defendants.
`
`STIPULATION AND i!:R:dl'm't'If ORDER
`TO DISMISS CERTAIN
`COUNTERCLAIMS
`
`WHEREAS Defendants Mylan Pharmaceuticals Inc., Mylan Labora ories Ltd., and Mylan
`
`Inc. (collectively, ''Mylan") pleaded counterclaims of noninfringement and i validity of U.S. Patent
`
`No. 9,220,698 ("'the '698 patent") in the above-referenced action Civil A tion No. 15-cv-03327
`
`(consolidated as Civil Action No. 15-cv-03322) ("Case II");
`
`WHEREAS Plaintiffs Horizon Pharma Inc. ("Horizon") and
`
`ozen, Inc. ("Pozen")
`
`(collectively, "Plaintiffs") alleged infringement of the '698 patent by Defen ants in a later action,
`
`Civil Action No. I 6-cv-0492 I ("Case III") in this Court;
`
`WHEREAS Plaintiffs and Mylan exchanged contentions for the '69 patent pursuant to L.
`
`Pat. R. 3.3 and 3.6 and the Scheduling Order (D.E. 42 in Civil Action No. l 5.~cv-003322) in Case II
`
`and L. Pat. R. 3.3 and 3.6 and the Scheduling Order (D.E. 40) in Case III;
`
`WHEREAS Plaintiffs also alleged infringement of U.S. Patent No. 9,393,208 ("the '208
`
`patent") by Defendants in Case III;
`
`WHEREAS the '208 patent is a continuation of the '698 patent;
`
`WHEREAS Plaintiffs and Defendants seek to promote judicial efficie ·,cy;
`
`2
`
`MYLAN PHARMS. INC. EXHIBIT 1047 PAGE 1
`
`
`
`Case 3:15-cv-03327-MLC-DEA Document 40 Filed 02/23/17 Page 2 of 3 PageID: 710
`
`THEREFORE, IT IS HEREBY STIPULATED, CONSENTED, AN ·;AGREED TO by and
`
`between the parties hereto as follows:
`
`1.
`
`The parties stipulate to dismiss Mylan's sixth and twelfth cou terclaitns (declaratory
`
`judgment of noninfringement and invalidity of U.S. Patent No. 9,220,69 , respectively) in the
`
`above-referenced action, Case II, without prejudice. This stipulation of dismissal does not apply to
`
`the claims or counterclaims related to the '698 and '208 patents in Case III.
`
`So stipulated,
`
`Dated: February 17, 2017
`
`Respectfully Submitted,
`
`s/ Gregory D. Miller
`By:
`Gregory D. Miller
`(GMiller@rivkin.com)
`Nancy A. Del Pizzo
`(Nancy.Delpizzo@rivkin.com)
`Gene Y. Kang
`(Gene.Kang@rivkin.com)
`RIVKIN RADLER LLP
`21 Main Street, Suite 158 ·
`Hackensack, NJ 07601
`(201) 287-2460 (telephone)
`(202) 489-0495 (facsimile)
`
`Shannon M. Bloodworth
`(SBloodworth@perkinscoie.com)
`Brandon M. White
`(BMWhite@perkinscoie.com)
`Robert Swanson
`(RSwanson@perkinscoie.com)
`PERKINS Corn LLP
`700 Thirteenth StreetN.W., Suite 600
`Washington, D.C. 20005-3960
`(202) 654-6200 (telephone)
`(202) 654-9134 (facsimile)
`
`Autumn N. Nero
`(ANero@perkinscoie.com)
`Melody K. Glazer
`(MGlazer@perkinscoie.com)
`Emily Greb
`
`1
`
`s/ John E. Flaher
`By:
`John E. Flaherty
`Jonathan M. H. Short
`McCARTER & ENGLIS
`Fout Gateway Center
`100 Mulberry Street
`Newark, New Jersey 0710
`(973) 622-4444
`
`, LLP
`
`Of Counsel for Plaintiffs A : traZeneca AB,
`Inc.
`AstraZeneca LP, and KB!-
`
`Stephen M. Hash
`Jeff Gritton
`BAKER BOTTS, LLP
`98 Jacinto Boulevard, Suit 1500
`Austin, TX 98701-4078
`(512) 322-2587 (telephone
`(512) 322-3687 (facsimile)
`
`Of Counsel for Plaintiff Po en Inc.
`
`Ricardo Rodriguez
`COOLEYLLP
`31 7 5 Hanover Street
`Palo Alto, CA 94304-1130
`( 650) 843-5000
`
`Of Counsel for Plaintiff Ho izon Pharma,
`Inc.
`
`3
`
`MYLAN PHARMS. INC. EXHIBIT 1047 PAGE 2
`
`
`
`Case 3:15-cv-03327-MLC-DEA Document 40 Filed 02/23/17 Page 3 of 3 PageID: 711
`
`Ii
`
`:11
`'I
`·.1
`
`1
`
`(EGreb@perkinscoie.com)
`PERKINS COIE LLP
`One East Main Street, Suite 20 I
`Madison, Wisconsin 53703-5118
`(608) 663-7460 (telephone)
`(608) 663-7499 (facsimile)
`
`Bryan D. Beel
`(BBeel@perkinscoie.com)
`PERKINS COIE LLP
`1120 NW Couch Street, 10th Floor
`Portland, OR 97209
`(503) 727-2000 (telephone)
`(503) 346-2116 (facsimile)
`
`Attorneys.for Defendants/Counterclaim
`Pfoint?ffs Mylan Pharmaceuticals Inc.,
`Mylan laboratories ltd., and
`Mylan Inc.
`
`IT IS SO ORDERED.
`
`Dated: efl/002.-/11
`
`I
`
`I
`
`4
`
`MYLAN PHARMS. INC. EXHIBIT 1047 PAGE 3
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
